| Literature DB >> 27959888 |
Idlir Licaj1, Bjarne Koster Jacobsen1, Randi Marie Selmer2, Gertraud Maskarinec3, Elisabete Weiderpass1,4,5,6, Inger Torhild Gram1.
Abstract
BACKGROUND: We prospectively investigated the association between different measures of smoking exposure and the risk of serous, mucinous, and endometrioid ovarian cancers (OC) in a cohort of more than 300 000 Norwegian women.Entities:
Mesh:
Year: 2016 PMID: 27959888 PMCID: PMC5243998 DOI: 10.1038/bjc.2016.418
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Baseline characteristics of the analytical sample according smoking status, Norwegian women, N=300 398 (1974–2013)
| Mean age at enrolment (95% CI) | 43.6 (43.6–43.7) | 43.0 (43.0–43.1) | 41.7 (41.6–41.7) | 42.2 (42.1–42.2) |
| Number of OC | 926 | 454 | 956 | 1410 |
| Number of invasive OC | 704 | 314 | 629 | 943 |
| Number of borderline OC | 222 | 140 | 327 | 467 |
| Number of serous OC | 497 | 261 | 484 | 745 |
| Number of mucinous OC | 130 | 69 | 241 | 310 |
| Number of endometrioid OC | 90 | 36 | 64 | 100 |
| Number of clear cell OC | 40 | 22 | 20 | 42 |
| Number of other OC | 169 | 66 | 147 | 213 |
| Arithmetic mean age at diagnosis for OC (95% CI) | 58.6 (57.9–59.2) | 56.5(55.6–57.4) | 55.5 (55.1–56.1) | 55.9 (55.4–56.3) |
| Mean age at diagnosis for invasive (95% CI) | 59.5 (58.7–60.2) | 57.5 (56.5–58.5) | 56.1 (55.4–56.8) | 56.6 (56.0–57.1) |
| Mean age at diagnosis for borderline (95% CI) | 55.7 (54.4–57.0) | 54.2 (52.6–55.8) | 54.5 (53.6–55.4) | 54.4 (53.6–55.2) |
| Mean age at diagnosis for serous (95% CI) | 59.1 (58.2–59.9) | 56.4 (55.3–57.5) | 55.8 (55.1–56.5) | 56.0 (55.4–56.6) |
| Mean age at diagnosis for mucinous (95% CI) | 56.9 (55.1–58.8) | 55.4 (53.0–57.8) | 54.6 (53.5–55.7) | 54.8 (53.8–55.8) |
| Mean age at diagnosis for endometrioid (95% CI) | 56.7 (54.6–58.8) | 55.0 (52.6–57.4) | 54.4 (52.4–56.5) | 54.6 (53.1–56.2) |
| Mean age at diagnosis for clear cells (95% CI) | 57.3 (54.0–60.6) | 56.2 (52.4–60.1) | 56.6 (53.2–60.1) | 56.4 (53.9–58.9) |
| Mean age at diagnosis for other OC (95% CI) | 59.8 (58.0–61.5) | 58.9 (56.2–61.6) | 56.5 (54.9–58.1) | 57.3 (55.9–58.7) |
| Follow-up time in years (age exit and age at enrolment) | 20.1 (20.0–20.1) | 18.9 (18.9–19.0) | 19.9 (19.8–19.9) | 19.5 (19.5–19.6) |
| Null parity, % | 13.2 | 10.2 | 11.8 | 11.2 |
| Mean number of children | 2.6 (2.6–2.6) | 2.4 (2.4–2.4) | 2.4 (2.4–2.4) | 2.4 (2.4–2.4) |
| Mean age at first childbirth | 25.0 (25.0–25.0) | 24.5 (24.4–24.5) | 22.9 (22.9–22.9) | 23.5 (23.5–23.5) |
| Physical activity, % | ||||
| Low | 20.3 | 19.5 | 25.2 | 23.1 |
| Middle | 58.1 | 55.8 | 56.7 | 56.4 |
| High | 21.6 | 24.7 | 18.1 | 20.5 |
| Education in years | ||||
| Low (<10) | 20.0 | 20.51 | 32.0 | 27.9 |
| Moderate(10–12) | 51.9 | 57.34 | 57.3 | 57.3 |
| High(⩾13) | 28.1 | 22.15 | 10.7 | 14.8 |
| BMI (kg m−2) | 25.0 (24.9–25.0) | 25.0 (25.0–25.1) | 24.1 (24.0–24.1) | 24.4 (24.4–24.4) |
| Age at smoking initiation | NA | 18.3 (18.2–18.3) | 20.5 (20.5–20.6) | 20.1 (20.0–20.2) |
Abbreviations: BMI=body mass index; CI=confidence interval; NA=not applicable; OC=ovarian cancer.
Parous women.
For current and former smokers.
Multivariablea HRs (95% CI) of invasiveness status and by histological subtypes according of OCs according to various measures of smoking status compared with never smokers 300 398 Norwegian women
| Never | 222 | 1.00 | 704 | 1.00 | 497 | 1.00 | 130 | 1.00 | 90 | 1.00 | ||||||||||
| Former | 140 | 1.23 (0.99–1.52) | 314 | 0.95 (0.83–1.08) | 261 | 1.03 (0.88–1.20) | 69 | 1.09 (0.81–1.47) | 36 | 0.83 (0.56–1.23) | ||||||||||
| Current | 327 | 1.55 (1.29–1.85) | 629 | 0.97 (0.86–1.08) | 484 | 0.99 (0.87–1.13) | 241 | 2.09 (1.67–2.62) | 64 | 0.74 (0.53–1.03) | ||||||||||
| Ever | 467 | 1.42 (1.20–1.68) | 943 | 0.96 (0.87–1.06) | 745 | 1.00 (0.89–1.13) | 310 | 1.70 (1.37–2.10) | 100 | 0.77 (0.57–1.04) | ||||||||||
| ⩽9 | 56 | 1.23 (0.91–1.65) | 98 | 0.95 (0.78–1.15) | 98 | 0.99 (0.80–1.23) | 26 | 1.05 (0.68–1.60) | 15 | 0.87 (0.50–1.50) | ||||||||||
| 10–19 | 56 | 1.18 (0.87–1.58) | 108 | 0.96 (0.80–1.16) | 108 | 1.04 (0.84–1.28) | 28 | 1.07 (0.71–1.62) | 19 | 1.06 (0.64–1.74) | ||||||||||
| 20+ | 25 | 1.25 (0.82–1.91) | 51 | 0.89 (0.68–1.18) | 51 | 1.13 (0.84–1.52) | 13 | 1.12 (0.63–2.00) | 2 | 0.28 (0.07–1.14) | ||||||||||
| | 0.07 | 0.53 | 0.47 | 0.04 | 0.18 | |||||||||||||||
| ⩽9 | 18 | 1.25 (0.74–2.09) | 28 | 0.91 (0.65–1.28) | 28 | 0.95 (0.64–1.42) | 13 | 1.64 (0.90–2.98) | 6 | 1.01 (0.42–2.45) | ||||||||||
| 10–19 | 64 | 1.27 (0.95–1.68) | 96 | 0.87 (0.72–1.05) | 96 | 0.85 (0.68–1.07) | 51 | 1.73 (1.24–2.42) | 11 | 0.54 (0.28–1.01) | ||||||||||
| 20+ | 243 | 1.68 (1.38–2.04) | 359 | 1.02 (0.90–1.16) | 359 | 1.04 (0.90–1.21) | 175 | 2.26 (1.77–2.89) | 47 | 0.84 (0.57–1.23) | ||||||||||
| | <0.001 | 0.75 | 0.24 | <0.001 | 0.11 | |||||||||||||||
| ⩽5 | 76 | 1.15 (0.88–1.49) | 153 | 0.98 (0.83–1.15) | 153 | 1.05 (0.87–1.26) | 36 | 0.98 (0.67–1.42) | 20 | 0.79 (0.48–1.28) | ||||||||||
| 6–15 | 44 | 1.22 (0.88–1.69) | 68 | 0.84 (0.67–1.05) | 68 | 0.86 (0.67–1.11) | 24 | 1.21 (0.78–1.88) | 15 | 1.11 (0.64–1.93) | ||||||||||
| 16+ | 15 | 1.60 (0.94–2.72) | 33 | 1.11 (0.76–1.62) | 33 | 1.64 (1.14–2.34) | 5 | 0.97 (0.39–2.39) | 1 | 0.31 (0.04–2.24) | ||||||||||
| | 0.025 | 0.61 | 0.89 | 0.13 | 0.28 | |||||||||||||||
| ⩽5 | 48 | 1.17 (0.85–1.62) | 86 | 0.86 (0.70–1.05) | 86 | 0.96 (0.76–1.22) | 32 | 1.37 (0.92–2.04) | 9 | 0.52 (0.26–1.06) | ||||||||||
| 6–15 | 165 | 1.51 (1.22–1.86) | 237 | 1.03 (0.90–1.18) | 237 | 0.92 (0.78–1.08) | 147 | 2.44 (1.90–3.14) | 36 | 0.83 (0.55–1.24) | ||||||||||
| 16+ | 111 | 1.90 (1.49–2.43) | 159 | 0.96 (0.80–1.15) | 159 | 1.15 (0.95–1.39) | 60 | 1.95 (1.41–2.70) | 19 | 0.88 (0.52–1.48) | ||||||||||
| | <0.001 | 0.50 | 0.84 | <0.001 | 0.29 | |||||||||||||||
| ⩽5 | 41 | 1.31 (0.94–1.83) | 74 | 0.97 (0.78–1.20) | 74 | 1.06 (0.83–1.36) | 17 | 0.95 (0.57–1.59) | 13 | 1.1 (0.61–1.98) | ||||||||||
| 6–15 | 73 | 1.10 (0.84–1.43) | 136 | 0.92 (0.78–1.09) | 136 | 0.93 (0.77–1.13) | 43 | 1.19 (0.84–1.69) | 17 | 0.67 (0.4–1.14) | ||||||||||
| 16+ | 23 | 1.53 (0.99–2.36) | 45 | 1.03 (0.75–1.42) | 45 | 1.43 (1.05–1.95) | 8 | 1.02 (0.50–2.10) | 6 | 1.11 (0.48–2.55) | ||||||||||
| | 0.08 | 0.68 | 0.29 | 0.98 | 0.25 | |||||||||||||||
| ⩽5 | 31 | 1.21 (0.83–1.77) | 52 | 0.80 (0.62–1.03) | 52 | 0.89 (0.67–1.19) | 21 | 1.44 (0.91–2.29) | 4 | 0.38 (0.14–1.05) | ||||||||||
| 6–15 | 221 | 1.49 (1.22–1.81) | 342 | 1.02 (0.90–1.16) | 342 | 0.99 (0.85–1.14) | 175 | 2.18 (1.71–2.77) | 48 | 0.82 (0.57–1.19) | ||||||||||
| 16+ | 73 | 2.02 (1.53–2.67) | 88 | 0.94 (0.75–1.17) | 88 | 1.05 (0.83–1.33) | 46 | 2.46 (1.73–3.50) | 12 | 0.89 (0.48–1.65) | ||||||||||
| | <0.001 | 0.66 | 0.81 | <0.001 | 0.28 | |||||||||||||||
| 20+ | 14 | 1.03 (0.58–1.83) | 34 | 1.16 (0.80–1.68) | 34 | 1.42 (0.97–2.08) | 5 | 0.61 (0.24–1.54) | 3 | 1.10 (0.32–3.80) | ||||||||||
| ⩽19 | 37 | 1.11 (0.75–1.66) | 67 | 1.19 (0.89–1.59) | 67 | 1.18 (0.87–1.59) | 20 | 1.30 (0.75–2.25) | 8 | 1.08 (0.46–2.54) | ||||||||||
| | 0.04 | 0.12 | 0.69 | 0.51 | 0.28 | |||||||||||||||
| 20+ | 163 | 1.48 (1.20–1.82) | 237 | 0.95 (0.84–1.09) | 237 | 0.90 (0.77–1.06) | 136 | 2.12 (1.65–2.72) | 34 | 0.72 (0.48–1.09) | ||||||||||
| ⩽19 | 163 | 1.63 (1.30–2.03) | 246 | 1.01 (0.86–1.17) | 246 | 1.11 (0.94–1.32) | 105 | 2.03 (1.53–2.69) | 30 | 0.84 (0.54–1.33) | ||||||||||
| | <0.001 | 0.51 | 0.57 | <0.001 | 0.23 | |||||||||||||||
Abbreviations: BMI=body mass index; CI=confidence interval; HR=hazard ratios; OC=ovarian cancer.
Adjusted for number of children (0, 1, 2, and ⩾3), age at first childbirth (<20, 20–24, 25–29, and ⩾30 years), BMI (<25, 25–29, and ⩾30 kg m−2), and level of physical activity (low, moderate, and heavy).
All histological subtypes.
Include invasive and borderline tumours.
Trend tests include never smokers.
Multivariablea HR (95% CI) of serous and mucinous epithelial OC overall by invasive status according to various measures of smoking status at enrolment compared with never smokers in 300 398 Norwegian women
| Never | 45 | 1.00 | 85 | 1.00 | 371 | 1.00 | 126 | 1.00 |
| Former | 21 | 1.01 (0.60–1.70) | 48 | 1.14 (0.80–1.63) | 175 | 0.94 (0.79–1.13) | 86 | 1.27 (0.96–1.67) |
| Current | 72 | 1.78 (1.20–2.64) | 169 | 2.26 (1.71–2.97) | 342 | 0.94 (0.81–1.10) | 142 | 1.11 (0.86–1.43) |
| Ever | 93 | 1.49 (1.03–2.16) | 217 | 1.81 (1.40–2.35) | 517 | 0.94 (0.82–1.08) | 228 | 1.17 (0.93–1.47) |
|
| ||||||||
| ⩽9 | 7 | 0.65 (0.29–1.44) | 32 | 1.42 (0.94–2.15) | 88 | 0.95 (0.75–1.20) | 38 | 1.10 (0.76–1.60) |
| 10–19 | 27 | 1.42 (0.88–2.31) | 52 | 1.42 (1.00–2.01) | 143 | 0.90 (0.74–1.09) | 61 | 1.07 (0.79–1.47) |
| 20+ | 58 | 1.89 (1.25–2.86) | 130 | 2.25 (1.68–3.01) | 283 | 0.97 (0.83–1.15) | 127 | 1.25 (0.97–1.63) |
| | 0.001 | <0.001 | 0.46 | 0.12 | ||||
|
| ||||||||
| ⩽5 | 19 | 0.94 (0.55–1.61) | 49 | 1.22 (0.85–1.74) | 169 | 0.98 (0.81–1.18) | 70 | 1.14 (0.85–1.53) |
| 6–15 | 55 | 1.96 (1.30–2.96) | 116 | 2.20 (1.65–2.95) | 225 | 0.90 (0.76–1.07) | 80 | 0.92 (0.69–1.22) |
| 16+ | 17 | 1.37 (0.77–2.46) | 48 | 2.05 (1.41–2.96) | 118 | 1.00 (0.80–1.24) | 74 | 1.76 (1.30–2.38) |
| | 0.07 | 0.01 | 0.35 | 0.01 | ||||
|
| ||||||||
| ⩽5 | 11 | 1.02 (0.52–1.98) | 26 | 1.21 (0.78–1.88) | 84 | 0.89 (0.70–1.12) | 42 | 1.28 (0.90–1.83) |
| 6–15 | 67 | 1.68 (1.13–2.49) | 151 | 1.93 (1.46–2.54) | 349 | 0.96 (0.82–1.12) | 129 | 1.00 (0.77–1.29) |
| 16+ | 15 | 1.68 (0.92–3.08) | 39 | 2.18 (1.48–3.23) | 80 | 0.95 (0.74–1.22) | 53 | 1.66 (1.19–2.31) |
| | 0.008 | <0.001 | 0.60 | 0.02 | ||||
|
| ||||||||
| 25+ | 14 | 1.36 (0.74–2.48) | 28 | 1.61 (1.05–2.48) | 78 | 0.94 (0.74–1.21) | 24 | 0.95 (0.61–1.47) |
| 20–24 | 32 | 2.02 (1.27–3.23) | 67 | 2.33 (1.68–3.23) | 120 | 0.88 (0.71–1.08) | 49 | 1.07 (0.76–1.50) |
| <20 | 32 | 1.61 (0.98–2.64) | 93 | 2.12 (1.53–2.92) | 213 | 1.06 (0.88–1.28) | 100 | 1.19 (0.89–1.59) |
| | 0.97 | 0.04 | 0.27 | 0.03 | ||||
Abbreviations: BMI=body mass index; CI=confidence interval; HR=hazard ratios; OC=ovarian cancer.
Adjusted for number of children (0, 1, 2, and ⩾3), age at first childbirth (<20, 20–24, 25–29, and ⩾30 years), BMI (<25, 25–29, and ⩾30 kg/m2), and level of physical activity (sedentary, moderate, and heavy).
Multivariablea hazard ratios (95% confidence interval) of three combined smoking characteristicsb (duration in years, number of cigarettes per day and age at start) and serous mucinous and endometrioid tumours in 300 398 Norwegian women
| Category 1 | 25 | 0.73 (0.49–1.09) | 18 | 1.48 (0.91-2.4) | 22 | 0.87 (0.57-1.34) | 10 | 1.47 (0.77-2.82) | 4 | - |
| Category 2 | 10 | 0.99 (0.53–1.88) | 4 | – | 8 | – | 1 | – | 2 | – |
| Category 3 | 20 | 0.99 (0.63–1.54) | 5 | – | 13 | 0.85 (0.49–1.47) | 4 | – | 2 | – |
| Category 4 | 13 | 1.38 (0.78–2.44) | 6 | – | 12 | 1.30 (0.71–2.37) | 4 | – | 1 | – |
| Category 5 | 132 | 0.94 (0.78–1.13) | 46 | 1.10 (0.80–1.51) | 91 | 0.93 (0.74–1.17) | 34 | 1.36 (0.93–2.00) | 9 | – |
| Category 6 | 34 | 0.95 (0.67–1.35) | 17 | 1.13 (0.68–1.87) | 28 | 0.90 (0.61–1.33) | 10 | 1.35 (0.70–2.61) | 7 | – |
| Category 7 | 330 | 1.00 (0.87–1.14) | 178 | 1.69 (1.38–2.08) | 239 | 0.98 (0.83–1.15) | 143 | 2.42 (1.88–3.10) | 35 | 0.83 (0.55–1.24) |
| Category 8 | 166 | 1.03 (0.85–1.23) | 99 | 1.55 (1.20–2.00) | 165 | 1.20 (0.99–1.45) | 56 | 1.77 (1.26–2.49) | 15 | 0.71 (0.40–1.28) |
Category 1: smoked <10 years, <10 years cigarettes per day, age at start ⩾18 years.
Category 2: smoked <10 years, <10 years cigarettes per day, age at start <18 years.
Category 3: smoked <10 years, ⩾10 years cigarettes per day, age at start ⩾18 years.
Category 4: smoked ⩾10 years, <10 years cigarettes per day, age at start ⩾18 years.
Category 5: smoked <10 years, ⩾10 years cigarettes per day, age at start <18 years.
Category 6: smoked ⩾10 years, <10 years cigarettes per day, age at start <18 years.
Category 7: smoked ⩾10 years, ⩾10 years cigarettes per day, age at start ⩾18 years.
Category 8: smoked ⩾10 years, ⩾10 years cigarettes per day, age at start <18 years.
Adjusted for number of children (0, 1, 2, ⩾3), age at first childbirth (<20, 20–24, 25–29, ⩾30 years), BMI (<25, 25–29, ⩾30 kg m−2) and level of physical activity (sedentary, moderate, heavy).
Only HRs and 95% CI with more than 10 cases are shown.
All histological subtypes.
Include invasive and borderline tumours.